Goldstein E J
R. M. Alden Research Laboratory, Santa Monica-UCLA Medical Center, USA.
Clin Infect Dis. 1996 Dec;23 Suppl 1:S25-30. doi: 10.1093/clinids/23.supplement_1.s25.
The currently available fluoroquinolones have modest activity against anaerobes. Newer fluoroquinolones with increased in vitro activity against anaerobes are under development and include levofloxacin, clinafloxacin, sparfloxacin, trovafloxacin, grepafloxacin, and DU-6859a. Side effects of the quinolones have varied according to the specific compounds and include central nervous system stimulation, gastrointestinal disturbances, vasculitis, and photosensitization. Monitoring for toxicity is incompletely reliable in identifying all potential serious side effects such as the "temafloxacin syndrome." Other fluoroquinolones may produce this syndrome rarely or not at all. In this paper, I review limited published studies on the use of these agents for skin and skin-structure infections and gynecologic infections. Studies in progress are noted, and when available, in vitro data on the efficacy of these agents against bacterial isolates from specific sources are reviewed and evaluated in terms of potential clinical utility.
目前可用的氟喹诺酮类药物对厌氧菌的活性一般。正在研发对厌氧菌体外活性增强的新型氟喹诺酮类药物，包括左氧氟沙星、克林沙星、司帕沙星、曲伐沙星、格帕沙星和DU - 6859a。喹诺酮类药物的副作用因具体化合物而异，包括中枢神经系统刺激、胃肠道紊乱、血管炎和光敏反应。在识别所有潜在的严重副作用（如“替马沙星综合征”）方面，毒性监测并不完全可靠。其他氟喹诺酮类药物可能很少或根本不会产生这种综合征。在本文中，我回顾了关于这些药物用于皮肤及皮肤结构感染和妇科感染的有限已发表研究。记录了正在进行的研究，并在有可用数据时，根据潜在临床效用对这些药物针对特定来源细菌分离株的体外疗效数据进行回顾和评估。
